You are here:

rufinamide 100mg, 200mg, 400mg tablets (Inovelon)

Advice

Following a re-submission

rufinamide (Inovelon®) is accepted for restricted use within NHS Scotland as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years and older.

Adjunctive rufinamide significantly reduced the frequency of total seizures and tonic-atonic seizures and significantly improved seizure severity when compared to placebo in patients with LGS. Rufinamide is restricted to use in patients who have failed treatment with or are intolerant of alternative traditional antiepileptic drugs.

Drug Details

Drug Name: rufinamide 100mg, 200mg, 400mg tablets (Inovelon)
SMC Drug ID: 416/07
Manufacturer: Eisai Ltd
Indication: Seizures assocaited with Lennox-Gastaut syndrome in patients four years and older
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 10 November 2008

Archived Advice

Full submission 12 November 2007

Back